Allspring Global Investments Holdings LLC Boosts Stock Position in Repligen Co. (NASDAQ:RGEN)

Allspring Global Investments Holdings LLC grew its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 275,933 shares of the biotechnology company's stock after acquiring an additional 14,693 shares during the period. Allspring Global Investments Holdings LLC owned about 0.49% of Repligen worth $49,613,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of RGEN. Fortis Capital Advisors LLC purchased a new stake in Repligen in the fourth quarter worth about $35,000. Park Place Capital Corp increased its holdings in Repligen by 90.2% in the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 120 shares in the last quarter. Signaturefd LLC raised its stake in Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 86 shares during the period. International Assets Investment Management LLC purchased a new position in Repligen during the third quarter valued at approximately $51,000. Finally, UniSuper Management Pty Ltd bought a new position in shares of Repligen in the second quarter worth approximately $57,000. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on RGEN shares. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $170.00 to $210.00 and gave the company an "overweight" rating in a research report on Wednesday, December 20th. Stifel Nicolaus boosted their price objective on Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a research report on Thursday, February 22nd. Finally, KeyCorp increased their target price on Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $196.70.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, VP Ralf Kuriyel sold 3,517 shares of the business's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock valued at $5,039,532 over the last 90 days. 1.10% of the stock is owned by corporate insiders.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $4.55 during mid-day trading on Friday, reaching $171.53. The stock had a trading volume of 706,402 shares, compared to its average volume of 536,121. The business's 50 day moving average price is $192.16 and its 200 day moving average price is $173.03. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a market cap of $9.58 billion, a P/E ratio of 238.24, a price-to-earnings-growth ratio of 5.76 and a beta of 1.02. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $155.74 million for the quarter, compared to analysts' expectations of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company's revenue for the quarter was down 16.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.68 EPS. Research analysts expect that Repligen Co. will post 1.46 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.